Cannabis Law Report

OCTOBER 6, 2021

Flora will conduct thorough due diligence and honor the traditional FDA and NHS route in scientific processes to ensure consistency, quality, and delivery of cannabinoids for specific disease conditions, backed by data, with an initial focus on fibromyalgia, brain health, pain, and related research. Investor Relations: Evan Veryard.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

The Cannigma

MAY 19, 2021

Japanese authorities can prosecute citizens for violating its cannabis laws — even if they used it abroad. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. Shutterstock).

Law 137

Law Legalization Clinical Trials CBD 137

Cannabis Law Report

AUGUST 28, 2022

Cannabinoids are a class of chemical compounds found in the cannabis plant. There are over 100 cannabinoids, and they are responsible for the plant’s therapeutic effects. Cannabinoids interact with our body’s endocannabinoid system, which regulates many important functions, including mood, appetite, and pain.

Cannabinoids 52

Cannabinoids Trichome Treatment Clinical Trials 52

Cannabis Law Report

MARCH 7, 2023

Incannex Healthcare Limited, a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, announced that it has engaged Catalent (Catalent) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy (..)

Clinical Trials 52

Clinical Trials Therapy Pharmaceutical Medicine 52

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

JULY 23, 2021

We’re interested in how cannabinoids affect the nervous system, the brain, and in in particular, we’re very interested in Alzheimer’s disease,” said Dr. Tyrell Towle, director of chemistry and extraction at MedPharm. According to Towle, MedPharm’s researchers hope to find whether cannabinoids can treat symptoms or even prevent the disease.

DEA 105

DEA Clinical Trials Cannabinoids Extraction 105

Cannabis Law Report

AUGUST 19, 2021

Such products will generate sales of £690 million ($856 million, 811 million euros) in 2021, according to the Association for the Cannabinoid Industry (ACI). Britain has experienced a “quiet cannabis revolution” that has transformed it into “the world’s second largest consumer cannabinoids market”, ACI said.

Cannabinoids 105

Cannabinoids Seed-To-Sale Clinical Trials CBD 105

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. & Notice of 2021 Final Results.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

SEPTEMBER 2, 2021

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. Prohibition Partners has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which will probably have a large impact on the medicinal cannabis space.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Cannabinoids 105

Cannabis Law Report

SEPTEMBER 2, 2022

LOBEF signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 Funding for psychedelics research and clinical trials is certainly here to stay. Psychedelics biopharma company Lobe Sciences Ltd. Read more.

Clinical Trials 52

Clinical Trials Research and Development Cannabinoids Medicine 52

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

The Cannigma

JUNE 14, 2021

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. Junk’ cannabis ‘ill-suited for clinical trials’. The federally sanctioned cannabis “looks more like green talcum powder than marijuana,” according to the lawsuit.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

JANUARY 6, 2022

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Business 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

United Patients Group

JANUARY 8, 2023

This is because it contains cannabinoids, which have anti-inflammatory properties. Cannabinoids reduce inflammation in the body by limiting the amount of leukotrienes and prostaglandins that are released into your bloodstream when you’re injured, stressed or sick. Cannabis is anti-inflammatory.

Blood Pressure 105

Blood Pressure Sleep Cannabinoids Clinical Trials 105

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. Del Morgan & Co.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

FEBRUARY 2, 2022

The double-blind, randomised, placebo-controlled clinical trial took place over two years between 2017 and 2019 at the Center for Medicinal Cannabis Research at the University of California. Campaigners are calling for the government to revise the current laws and bring them up to date with contemporary data.

Medicine 52

Medicine Clinical Trials Consumption Sleep 52

Veriheal

APRIL 11, 2022

federal law , it has not yet been used in any commonly prescribed medicines. The company initiated the first legal transfer (as deemed by federal law) to the U.S. We could potentially develop north of 11,000 drugs that are cannabinoid-based. federal law. Since cannabis is still a Schedule I substance under U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

SEPTEMBER 10, 2021

They have a strong pedigree in drug development which fits perfectly with the commercial and clinical expertise we have built within the Clerkenwell Health team”. Octarine Bio is a synthetic biology company based in Copenhagen, Denmark, which aims to deliver innovative cannabinoid and psychedelic treatments to improve health and wellbeing.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

JULY 26, 2021

OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. About Skye Bioscience.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

Cannabis Law Report

AUGUST 10, 2022

The lead investigators are Jacobo Mintzer , MD, MBA, Brigid Reynolds , ANP-BC, and the Alzheimer’s Clinical Trial Consortium (ACTC).The ” Study Details – provided by Alzheimer’s Clinical Trial Consortium. BARRIE, ON , Aug. 9, 2022 /CNW/ – MediPharm Labs Corp. MediPharm Labs Corp.

Clinical Trials 52

Clinical Trials Medicine Pharmaceutical THC 52

Cannabis Law Report

JANUARY 11, 2022

DENVER–(BUSINESS WIRE)– Ripple , Colorado’s trusted cannabis edibles brand and pioneer of fast-acting and clinically proven technology, is leading the way in cannabis wellness with new Ripple Sleep QuickDissolves and Ripple Sleep QuickGummies. Our mission is to improve people’s lives through cannabinoids.

THC 52

THC Clinical Trials Research and Development Sleep 52

Cannabis Law Report

OCTOBER 5, 2021

is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. Rex Merchant.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment. Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

JANUARY 19, 2022

Having retired after 35 years in elected office, Congressman Moran is now with a major law firm and represents international and domestic clients in the defense, technology, entertainment and international diplomacy sectors. IGC), headquartered in Maryland, engages in the development of cannabinoid-based therapies for healthcare applications.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

JANUARY 4, 2022

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’s Board of Directors, effective February 1 st , 2022. Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

FEBRUARY 15, 2019

The Singapore Online Citizen reports… Law & Home Affairs Minister K Shanmugam says that pharmaceutical companies are hiding their intentions behind a smokescreen when it comes to cannabis. On the other hand, they found that are some medicine with cannabinoid products that are scientifically researched and medically approved.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Cannabis Law Report

SEPTEMBER 14, 2021

A lack of consumer trust, transparency and scientific rigor has hampered the CBD and cannabinoid industry from reaching its growth potential for far too long”. About Radicle Science. Radicle Science is a transformative healthtech B-corp offering the first ever path to natural product validation at scale.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

AUGUST 6, 2021

CBD, which is an abbreviation for Cannabidiol, is one of Cannabis’s primary components – one of its primary Cannabinoids. Cannabinoids are the naturally occurring compounds found in the Cannabis plant. There are over 480 different Cannabinoids in the Cannabis plant. It is non-psychoactive and has a multitude of health benefits.

CBD 105

CBD Wellness and Beauty Treatment Pharmaceutical 105